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Liver disease has grown to become one of the most 
common causes of premature death in the UK and its 
burden continues to escalate. 62,000 years of working 
life are lost to liver disease every year and its impact on 
the poorest in our society is disproportionally severe, 
contributing to the widening of socioeconomic health 
inequalities in the UK.
Worsening liver disease health outcomes could be 
reversed through concerted preventive action to tackle its 
main causes: alcohol misuse, obesity and viral hepatitis. 
Voluntary agreements with the food and drinks and 
alcohol industries have proved ineffective.
Through this paper, the Foundation for Liver Research 
seeks to make the financial case for public health action 
in these areas and urges the implementation of targeted 
measures recommended by the independent Lancet 
Commission on Liver Disease. This paper summarises 
the escalating financial costs to the health and care 
system as well as the wider societal costs related to the 
three lifestyle-related risk factors. 
Worsening liver disease health 
outcomes could be reversed through 
concerted preventive action to tackle 
the main causes of liver disease.
!
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Executive 
summary
Alcohol misuse has been estimated to have a total societal cost in England 
and Wales of £21bn per year although more recent research suggests the  
true figure could be at least £27bn and as high as £52bn. Studies have 
identified severe cost challenges across many parts of society.
Alcohol misuse has contributed to escalating health burden and costs:
• Alcohol-related admissions increased approximately 17% between  
 2010/11 and 2015/16
• Working years lost due to alcohol rose from 46,000 in 2010 to 167,000  
 in 2015,16% of all working years lost in England
• The number of claimants of Employment Support Allowance and  
 Incapacity Benefit / Severe Disablement Allowance citing alcohol  
 misuse as the primary medical condition grew from 38,910 in  
 May 2011 to 57,940 in May 2015
 Unless the trends are reversed, it is projected  
 that over the next five years, £17 billion in costs  
 to the NHS will be incurred.
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Alcohol misuse
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CHILD 
SERVICES
Up to £2.8bn per year 
in England
NHS
£3.5bn per year 
in England
CRIME
Up to £13bn per year 
in the UK
LOST  
PRODUCTIVITY
£7.3bn per year 
in the UK
COST 
CHALLENGES
RECOMMENDATIONS
• Minimum unit price (MUP) for alcohol: The first five years of a 50p MUP would generate £1.1bn of savings  
 in total direct costs, whilst the total societal value would be worth £3bn. Scotland is awaiting the conclusion of  
 a legal challenge on MUP led by the Scotch Whisky Association, whilst Wales also intends to legislate for MUP
• Re-introduce the alcohol duty escalator: A duty escalator 2% above inflation would result in a total saving of  
 £226.9m to the NHS over a five year period
• New higher duty band for cider based on alcohol content between 5.5% and 7.5%: A 500ml can of cider at  
 7.5% ABV generates 19p duty, compared with 69p on a can of beer of equivalent size and strength. The Republic  
 of Ireland has a higher rate of tax for cider above 6% to mitigate its harmful impact
• Restrict trading hours for off-licence to 10am-10pm and limit alcohol availability for on-licence after  
 midnight: Australia has demonstrated large reductions in non-domestic assault by restricting trading hours
• Stronger regulation of alcohol marketing and advertising: Removing exposure to TV advertising for  
 11-18 year olds would lead to a fall of 9% in alcohol consumption
Obesity
!
With 63% of adults aged over 16 obese or overweight in 2015, and one in three 
children in England obese or overweight by the time they leave primary school,  
the obesity epidemic is reaching a crisis point. A range of studies have broken 
down the cost challenges. 
The burden and associated costs of obesity have escalated in recent years:
•  The cost to society has grown from £15.8bn in 2007 to £27bn in 2016;  
 the Treasury has suggested the figure could already be £46bn per year
•  Finished hospital admission episodes where obesity was a primary  
 or secondary diagnosis increased 150% from 211,783 in 2010/11  
 to 525,000 in 2015/16
•  NHS spending on obesity-related conditions soared 65% in 10 years  
 to £1.027bn each year
 Failure to take action on obesity could result in  
 added health costs to the UK of £1.9-2bn each year  
 and a £14bn cost to businesses annually by 2035.
£
SOCIAL  
CARE
£352m per year 
in England
NHS
£6.1bn per year 
in England
WELFARE
Up to £6bn per year 
in England
LOST  
PRODUCTIVITY
£5.6bn over 2 years 
in the UK
COST 
CHALLENGES
RECOMMENDATIONS
•  Implement further fiscal measures on foods high in sugar, salt and fat in addition to the Soft Drinks  
 Levy: NICE forecasted savings of £576m each year by year five if sugar was reduced to 5% of total daily  
 energy intake
•  Close the loopholes in advertising to ban adverts for junk food and sweets before the watershed at 9pm:  
 A review of 22 studies worldwide found a link between children’s exposure to junk food adverts and consumption
•  Introduce mandatory controls on supermarket price promotions for unhealthy food and drink: Public  
 Health England estimated that if future promotions were banned, 6.1% would be cut in overall sugar volume
• Offer weight loss surgery to obese people with diabetes: The initial cost of £6,000 for surgery pays for  
 itself within two to three years by reducing the health burden
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Viral hepatitis poses a major health risk to society and the 
associated costs are high. However, progress to overcome this  
cause of liver disease is hampered by gaps in data on the prevalence, 
health burden and financial costs of hepatitis B and C.  
The number of individuals chronically infected with hepatitis C in 
the UK was estimated to be 216,000, although other studies have 
suggested the true figure could be as high as 466,000 with 86% 
unaware they are infected. Hepatitis B has also become a major 
challenge for the UK, with a similarly large pool of people affected 
by the disease. Marginalised populations face a greater risk, notably 
individuals who inject drugs, prisoners and immigrant populations. 
Further efforts must be made to collate the necessary data to 
understand the total financial cost of viral hepatitis to society, but  
for hepatitis C alone, it is thought that lost productivity is worth up  
to £367m per year. 
Moreover, there are signs of escalation in recent years. For  
example, between 2010 and 2015, preliminary estimates of cases  
of hepatitis C-related cirrhosis or hepatocellular carcinoma 
increased from 1,336 to 1,692 in England.
New opportunities are presented by the recent introduction of novel 
oral antiviral treatments for hepatitis C into the NHS. There is a cost 
associated with these treatments, with the NHS making a £190m 
ring-fenced investment into the new antiviral medicines in 2015. 
However, NICE deems their use as cost-effective, mitigating even 
higher costs of complications of advanced liver disease. A study of 
five European countries found that hepatitis C treatment resulted in 
savings of £435m annually due to improvements in work productivity.
Viral hepatitis
£
RECOMMENDATIONS
•  Immunisation for all  
 individuals with risk factors  
 for hepatitis B: Immunisation  
 for babies born after 2018  
 should be extended to all  
 individuals with risk factors
•  Improve access to testing  
 and diagnosis of hepatitis:  
 Public health budgets must  
 be protected and boosted  
 to offer effective testing and  
 diagnosis in the community,  
 with a particular focus on  
 groups at greatest risk and/or  
 not in regular contact with  
 health services
•  Protect harm reduction   
 services: Funding for harm  
 reduction services must  
 be protected, and access  
 enhanced for individuals  
 in need in order to fulfil their  
 important role in reducing  
 the burden of hepatitis
!
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Disease detection and treatment of patients affected 
by viral hepatitis in the UK remains often sub-optimal.
Background: liver disease and its causes
The mounting liver disease epidemic is one of the most pressing public health concerns of our time.  
Liver disease constitutes a major cause of premature death in the UK, with mortality rates having 
increased four-fold since 1970.1  
Liver disease poses a particular threat to economic productivity because it affects people of younger  
age more severely than other big killer diseases. More than one in ten people who lose their life to liver 
disease die in their 40s and 90% of liver-related deaths occur in people under the age of 70.2  
Liver disease now accounts for more years of life lost amongst under-65s than lung and colorectal 
cancers combined (the two most common non-sex-specific cancers).3  
We also know that liver disease hits the poorest and the most vulnerable in society the hardest.  
People in the most disadvantaged quintile of the population are 2.3 times more likely to die from  
liver disease,4  making it one of the major factors in widening socioeconomic health inequalities.
Crucially, the trend of worsening liver disease health outcomes could be reversed through concerted 
preventive action to tackle the three main causes of liver disease: 
Between them, these lifestyle-related risk factors are responsible for the great majority of liver disease 
cases, and the Lancet Commission on Liver Disease has been urging resolute public health intervention 
in these areas since the publication of its seminal report, Addressing liver disease in the UK, in 2014.5 
Recent governments have prioritised voluntary agreements with the food and drinks and alcohol 
industries over mandatory regulatory measures. Voluntary agreements offered promise, but failed to 
deliver change in public health.6 Furthermore, a study by public health experts showed that self-regulation 
in the alcohol industry is proving ineffective,7  a conclusion backed up by Public Health England.8 
The new Government should break with the legacy of limited public health action in these areas and  
seek to implement robust preventive measures in line with the recommendations of the independent 
Lancet Commission on Liver Disease to avoid further escalation of the health and financial burden 
associated with the main causes of liver disease.
Obesity
Viral 
hepatitis
 
Excessive alcohol 
consumption
££
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Purpose of this paper
The health argument for more robust action on alcohol, obesity  
and viral hepatitis is well established.9,10 This paper does not seek  
to restate it but rather to supplement it by making the financial case  
for targeted public heath action to reduce the harm associated with 
excessive alcohol consumption, obesity and viral hepatitis.  
The health benefits of addressing these lifestyle-related risk factors 
would reach beyond liver disease and would deliver health improvement 
in cancer, cardiovascular disease as well as other disease areas. 
Crucially, effective preventive intervention in these areas would free up 
valuable financial resource, which could be re-invested into the health 
system experiencing ever-greater financial pressures. Furthermore, 
some of the most effective measures to overcome the main causes of 
liver disease will also boost gains to the Exchequer.
Targeted at high-level national decision-makers, this paper brings 
together the latest evidence of escalating financial costs associated  
with these risk factors. Drawing on a multitude of data sources,  
the paper sets out the financial costs to the health and care system,  
as well as the wider societal costs related to the three causes.  
We outline the costs observed in recent years and, where appropriate, 
make informed projections of the likely future financial burden.  
We further identify the financial benefits forgone as a result of the  
failure to take action and present a series of policy proposals, in line  
with the evidence-based recommendations of the Lancet Commission, 
for policymakers’ urgent consideration.
This paper focuses on alcohol, obesity and viral hepatitis; however,  
it should be noted that they are not the only liver disease risk factors. 
Smoking, for example, is a major aggravating factor and was estimated 
to be responsible for approximately 4% of all hospital admissions  
in England for those aged over 35 in 2013/14 at a significant cost  
to the NHS.11
The Lancet Commission on  
Liver Disease is a group of multi-
disciplinary experts assembled to 
make recommendations to reduce 
premature liver disease mortality, 
tackle liver disease burden from 
avoidable causes and improve the 
standard of care for patients with 
liver disease in hospital.
In its seminal report, Addressing 
liver disease in the UK, published 
in 2014, the Lancet Commission 
set out a blueprint for improving 
the prevention and management 
of liver disease in the UK and 
made a number of practical 
recommendations for action. 
Since then, the Lancet Commission 
has produced two progress reports 
and has continued its campaign 
for the implementation of its 
evidence-based recommendations 
through ongoing engagement with 
parliamentarians, policy-makers  
and health system leaders.
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Health and care system costs
The financial cost to the NHS of managing alcohol-related 
health issues was found to be a staggering £3.5bn in 
2009/10 – £120 for each taxpayer.18  This consisted of  
costs across all parts of the system including:
  £122m on specialist treatment
  £112m on GP consultations
  £1.8bn on inpatient/day visits  
  (including directly or partly attributable to alcohol)
  £246m on outpatient visits
  £8m on dependency prescribed drugs
  £696m on attendances to A&E
  £16m on practice nurse consultations
  £449m on ambulance services
Costs to the NHS have likely further increased given  
that alcohol-related admissions escalated approximately 
17% between 2010/11 and 2015/16.19 
The cost impact of alcohol reaches beyond the health 
system into social care. The Institute of Alcohol Studies 
(IAS) has estimated that the cost of alcohol for child 
services could sit as high as £2.8bn20 driven by a strong 
association between drinking and child neglect and 
mistreatment. One in five children live with a parent 
who drinks too much21 and the Centre for Public Health 
estimated that as much as 34% of child social care  
costs are alcohol-related.22 
Alcohol-related liver disease accounts for 60% of all liver disease and 84% of liver-related deaths.12   Alcohol 
consumption is also linked to a wide range of other medical conditions and diseases, including seven types of cancer.13  
The high levels of alcohol-related health burden show no signs of subsiding, with over 10 million adults regularly 
drinking more than 14 units of alcohol each week against the advice of the Chief Medical Officer.14 
The Government’s own figure for the total external cost – costs not directly borne by the drinker – of alcohol misuse 
for England and Wales is £21bn per year.15 It should be noted that this figure requires updating and is therefore likely 
to underestimate the true total cost.16 More recent studies of high-income countries with comparable methodologies 
could bring the figure up to £27bn and even as high as £52bn for 2016.
The societal financial burden associated with alcohol is set to continue rising, particularly as alcohol is 60% more 
affordable today than in 1980.17 The direction of travel in recent years has been contrary to tackling affordability of 
alcohol, with cuts to duty and the abolition of the alcohol duty escalator.
MYTHBUSTER
MYTH: Alcohol consumption is an individual  
choice that only has consequences for the drinker.
EVIDENCE: Alcohol abuse leads to significant 
third party risk and damage, for example, harming 
spouses, children, colleagues and many others 
across society.
Modelling has shown that over the next five years,  
alcohol will be accountable for:23 
• £17 billion in costs to the NHS, including 
 £638m in cancer treatment costs
• 63,000 deaths
• 4.2 million hospital admissions
The health systems of the devolved nations also face  
a significant financial burden on the health and care 
system due to alcohol: 
• Scotland as high as £392.8m cost to the health  
 system and as high as £346.8m to social care in 200724 
• Wales as high as £73.3m cost to the health system  
 in 2008/0925 
• Northern Ireland as high as £158m cost to the  
 health system and as high as £82m to social care  
 in 2008/0926
Prevention is crucial, but it is also important that reducing 
variation in treatment for harmful drinkers is not be 
overlooked. This is another important way to reduce the 
burden of alcohol misuse on the health service.
Alcohol misuse
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Unemployment  
and productivity
The Department of Health estimated that alcohol 
misuse in the UK costs the economy £7.3bn 
per year due to factors such as unemployment, 
sickness absence, early retirement from an inability 
to work and premature deaths among economically 
active people of working age.27 In 2015, 167,000 
working years were lost due to alcohol, 16% of all 
working years lost in England.28 This has grown 
considerably since 2010 when NICE estimated the 
figure stood at approximately 46,000.29 
Furthermore, as of May 2015, 57,940 claimants 
of Employment Support Allowance and Incapacity 
Benefit / Severe Disablement Allowance had 
alcohol misuse cited as the primary medical 
condition.30 This has escalated steeply from 38,910 
in May 2011.31 
In addition to unemployment, alcohol misuse 
represents a significant cost for UK business 
through limiting the productivity of its workforce. 
Members of the workforce who consume alcohol 
have higher levels of absenteeism and this costs 
businesses £1.7bn per year – 17m absent days  
at a cost to employers of £98.96 per day.32 
The devolved nations have also reported losses  
to productivity due to alcohol:
• Scotland  
 as high as £1bn33 
• Northern Ireland  
 as high as £258.2m34 
Crime and disorder
Previous estimates have suggested the cost to the UK 
taxpayer of alcohol-related crime and social disorder 
stands at up to £13bn each year.36 Physical and sexual 
assault, homicide, and anti-social behaviour are just 
a few examples of offences which exhibit positive 
correlation with alcohol consumption.
Alcohol-related crime is likely to be under-estimated 
as not all relevant offences are reported to the 
police;37 therefore, the true burden is likely to be 
understated. In cases that result in injury to the 
victim, there can be an added cost to the NHS. 
Furthermore, it should not be overlooked that half 
of respondents to an IAS survey of ambulance staff 
reported being injured at least once during call-outs 
to intoxicated members of the public.38 
Binge drinking continues to pose a challenge and 
has been shown to lead to a rise in public costs by 
increasing:39 
  Daily average of road accidents  
  by 17% – each fatal accident costs  
  on average £2.07m
  Average number of alcohol-related  
  arrests by 45% – each arrest  
  costs £14,836
  Number of police officers on duty  
  by 30% – £15 average hourly wage  
  per Police Constable
In addition, violent crimes are very often 
committed under the influence of alcohol:
• 40% in 2011/12 in England and Wales40  
• 54% in 2014/15 in Scotland41 
• 40% in 2015/16 in Northern Ireland42
MYTHBUSTER
MYTH: Intervention to reduce alcohol  
consumption would damage a valuable industry.
EVIDENCE: The benefits to public services and the 
economy of a reduction in alcohol consumption 
would far outweigh the potential negative impact 
on the UK alcohol industry’s £1.7bn surplus.35
MYTHBUSTER
MYTH: There is no added benefit of  
implementing MUP and duties policies together.
EVIDENCE: MUP and duties can complement each 
other, with the former targeting the cheapest alcohol 
consumed by the most harmful drinkers, and the  
latter tackling consumption in the wider population.
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 Introduce a minimum 
 unit price for alcohol
One policy that has attracted attention in recent years 
is setting a minimum price per unit of alcohol (MUP) 
– a minimum price below which a unit of alcohol 
cannot legally be sold. This measure would target 
the cheapest alcohol in supermarkets, as opposed to 
increasing the price in pubs or bars where alcohol is 
generally sold above the minimum threshold. 
The University of Sheffield’s Alcohol Research Group’s 
modelling, funded by the Policy Research Centre for 
Prevention at Cancer Research UK, finds that MUP at 
a level of 50p43 – the level legislated at by the Scottish 
Government44 – would have a significant impact:
In the first five years after implementation, the policy 
will lead to:
• 1,150 fewer deaths
• 74,500 fewer hospital admissions
Significant financial savings would be achieved  
over the first five years:
• £325.7m savings in healthcare costs
• £710.9m savings in crime costs
• £65.1m savings in workplace absence
• Total direct costs of £1.1bn 
 (healthcare, crime and absence) 
• Total societal value, including the value  
 of improved health, of £3bn
Furthermore, real world evidence from Canada  
shows that increases in minimum prices were 
associated with substantial reductions in deaths 
caused by alcohol.45
The Scottish Government plans to introduce MUP,  
but must await the conclusion of a lengthy legal 
challenge led by the Scottish Whiskey Association.  
In June 2017, the Welsh Government also announced 
its intention to legislate for MUP.
  Re-introduce the  
  alcohol duty escalator
The alcohol duty escalator saw the duty rate of  
alcohol increase by 2% above inflation each year; 
however, it was scrapped for beer in 2013 and for 
wine, cider and spirits in 2014.
The Treasury’s own forecasts show that scrapping  
the alcohol duty escalator reduced potential income 
to the Exchequer by £5bn over five years – £3.45bn 
taking into account consumption increases.46  
In 2016, modelling funded by the Policy Research 
Centre for Prevention at Cancer Research UK and 
carried out by the University of Sheffield’s Alcohol 
Research Group projected that, over five years, an 
escalator 2% above inflation would lead to a total of:47 
• 850 fewer alcohol-attributable deaths
• 56,000 fewer alcohol-attributable  
 hospital admissions
• A saving of £226.9m to the NHS
What can be done?
There are a number of policy levers that the Government can use to tackle these 
challenges by addressing the availability, affordability and acceptability of alcohol.
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MYTHBUSTER
MYTH: MUP would impact moderate drinkers.
EVIDENCE: The impact on moderate drinkers 
would be minimal. The policy would specifically 
target harmful drinkers who usually purchase 
alcohol below the MUP threshold.48
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 Restrict trading hours  
 for off and on-licences
Longer trading hours are associated with higher 
rates of alcohol-related harm. Lessons can be 
learnt from Australia where the introduction of 
policies to restrict trading hours have resulted 
in 45.1% and 20.3% reductions in non-domestic 
assault in the Kings Cross and CBD areas of 
Sydney respectively.53  
To reverse the damaging trends in the UK,  
off-licence opening hours should be restricted to 
between 10am and 10pm. In addition, on-licence 
trading should be restricted to limit the availability 
of alcohol after midnight.
 Strengthen regulation of  
 alcohol marketing and advertising
In 2011 Ofcom suggested that children on average watched 3.2 alcohol adverts per week  
on TV.54 Children exposed to alcohol marketing are more likely to start drinking alcohol, whilst 
those who already drink will consume greater quantities. Modelling undertaken in the UK  
found that removing exposure to TV advertising for 11-18 year olds would result in a 9% fall  
in alcohol consumption.55 
This paper supports the call by the AHA for a ban on sports sponsorship by alcohol brands,  
a watershed for alcohol adverts on television and restricting cinema adverts to showing alcohol 
products only before 18 certificate films, with a longer-term objective to prohibit all advertising.56
4
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 Introduce a new higher duty band  
 for cider between 5.5% and 7.5%
High strength cider has become the ‘drink of choice’ 
for many of the most at-risk drinkers.49 This is due 
to the design of the duty system that has allowed its 
price to be extremely low by being taxed according 
to its volume rather than alcohol content. A new 
higher duty band for cider based on alcohol content, 
set between 5.5% and 7.5% ABV would be the most 
effective way of making use of the tax system to tackle 
the proliferation of cheap, high strength ‘white’ ciders. 
A 500ml can of cider at 7.5% ABV generates 19p  
of duty, compared with 69p on a can of beer of 
equivalent size and strength, according to the  
Alcohol Health Alliance (AHA),50  whilst the Institute 
for Fiscal Studies has also highlighted the current 
structure’s limitations.51 
The Treasury has an opportunity to introduce a new 
duty band for ‘white’ ciders in response to its recent 
consultation on the issue. Lessons can be learnt from 
the Republic of Ireland where action has been taken 
to ensure that white cider does not have the same 
harmful impact as in the UK, by taxing cider above  
6% ABV at a much higher rate.52 
3
10
Health and care system costs
The direct cost to the NHS in England of people being 
overweight and obese was estimated at £6.1bn per 
year in 2016,69 uprated from £5.1bn in 2006/07.70  
In 2015/16, there were 525,000 finished hospital 
admission episodes where obesity was a primary or 
secondary diagnosis.71 This represents an increase 
of almost 150% from 2010/11 when the number of 
obesity-related hospital admissions stood at 211,783.72 
On top of this, the cost to social care stands at £352m, 
which includes extra formal hours of support for the 
severely obese.73 Severely obese individuals are also 
thought to be over three times more likely to need 
social care than those of a healthy weight.74 
The Obesity Health Alliance states that the health 
cost of obesity is the equivalent to at least:68
•  The salary of 165,000 nurses  
 or 85,000 hospital doctors
• 116,000 heart transplants
• 730,000 hip replacements
Excess body fat has contributed to premature 
mortality.75 In addition to liver disease, excess body 
fat has been a contributing factor to a range of 
serious conditions, including but not limited to:76 
  44% of diabetes cases
  23% of heart disease cases 
  Up to 41% of uterine cancer cases
  10% or more of liver, gallbladder,  
  colon and kidney cancers in the UK77 
£
The UK is in the midst of an obesity crisis. In 2015, 63% of adults aged over 16 were obese or overweight.57  
In addition, one in three children in England are already obese or overweight by the time they leave primary school.58  
The result has been an escalation in cases of non-alcoholic fatty liver disease in recent years,59 which is closely 
associated with a range of severe complications such as hepatocellular carcinoma.60 It is striking that the growing 
childhood obesity crisis has led to 38% of obese children showing evidence of non-alcoholic fatty liver disease.61 
In addition, obesity commonly compounds liver disease, for example heavy drinkers who are also overweight experience 
a higher risk of liver events than those who are a healthy weight.62  
The socioeconomic picture is concerning too, with 40% of year six children from the most deprived areas  
of England overweight or obese compared to 27% in the least deprived areas.63 The gap between the most  
and least deprived areas has been steadily widening since before 2010.64 
Projections estimated the total cost of obesity to health and the wider economy could have reached £27bn in 2016,65  
a dramatic rise from £15.8bn in 2007. By 2025, it is projected that the cost will have escalated to £37.2bn;66 however, 
more recently, the Treasury has suggested the figure could already be £46bn per year.67
11
Obesity
Productivity
The impact of obesity is also felt by UK 
businesses, faced with a less productive and an 
unhealthy workforce. This indirect cost to society 
was estimated in 2010/12 to have reached £5.6bn 
(excluding premature mortality).86 
Research shows that obese individuals are  
less likely to be in employment. The subsequent 
obesity-related welfare costs are thought to  
stand at as high as £6bn.87 The Department  
for Work and Pension’s figures for May 2015 
showed that 1,630 Employment Support 
Allowance claimants cited obesity as the main 
disabling condition;88 however, it is thought  
there are as many as 807,000 claimants with  
a main disabling condition for which obesity  
is potentially a contributory factor.89   
Obesity also has an impact on workforce 
productivity with NICE estimating that an 
organisation employing 1,000 people could face 
over £126,000 each year in lost productivity due 
to issues associated with obesity, such as back 
problems and sleep apnoea. NICE has estimated 
that 16m days of sickness absence per year are 
due to obesity.90 
Figures show NHS spending on conditions linked  
to obesity is £1.027bn each year, soaring 65%  
in ten years.78 
Projections have found that, on current trends, the 
UK will face added health costs of £1.9-2bn each 
year from obesity-related diseases with as many 
as 48% of men and 43% of women obese by 2030.79  
The rising levels of obesity could result in 670,000 
additional cases of cancer by 2035.80 
The financial burden of treating people who are 
overweight and obese in the devolved nations  
is also significant:
• Scotland £363m in health and care costs  
 in 2015, although the true cost could be  
 closer to £600m81  
• Wales £86m in 2008/0982  
• Northern Ireland £92m in 200983 
MYTHBUSTER
MYTH: The Soft Drinks Industry Levy  
will result in significant job losses in the soft  
drinks industry
EVIDENCE: The industry will remain competitive 
and successful:
•  Comparable taxes in the EU have not shown  
 any long-term impact on the competitiveness  
 of the food and drinks industry84
• HMRC expects the impact on business  
 to be negligible85
The growing loss of productivity 
to employers is projected to hit 
£14bn annually by 2035.91 
!
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 This paper welcomes the Government’s intention to implement the Soft Drinks 
Industry Levy. Previous research has estimated that implementation of the levy would 
result in 144,000 adults and children avoiding obesity every year, as well as preventing 
19,000 cases of Type 2 diabetes.92 The expected revenue for the Exchequer from 
the levy of £380m per year from 2018-1993 underlines the importance of this policy. 
Furthermore, Coca-Cola has already cut the sugar content of some of its products 
without undermining sales.94 This policy must represent just the first step.
What can be done?
There are a range of interventions that the Government should 
implement if the trend of growing obesity is to be challenged. 
  Close the loopholes in advertising  
 to ban adverts for junk food  
 and sweets from all TV shows  
 broadcast before the watershed
Existing regulations from Ofcom and the 
Committee of Advertising Practice on advertising 
junk food to children require strengthening. This 
should be in the form of a TV advertising ban before 
the watershed at 9pm. The loophole that allows 
advertising of junk food during TV programmes 
where children make up more than 25% of 
the audience means the full benefits to health 
outcomes and the associated cost savings will not 
be achieved.
The Food Standards Agency’s (FSA) analysis for 
Ofcom suggested significant financial benefits of 
banning adverts before the watershed at 9pm and 
called for more robust action.98 
A review of 22 studies worldwide found a link 
between children’s exposure to junk food adverts 
and consumption.99  
2
 Implement further fiscal measures 
 on foods high in sugar, salt and fat
Other fiscal measures on foods high in sugar, salt 
and fat must be introduced. A recent international 
study concluded that food taxes aimed at specific 
nutrients can reduce consumption and divert 
preferences to untaxed products.96 NICE forecasted 
savings of £576m per annum by year five for the 
NHS when it recommended that sugar should 
form no more than 5% of total daily energy intake.97 
Moreover, as set out above with the Soft Drinks 
Industry Levy, there is significant potential income 
that can be generated for the Exchequer through 
fiscal measures on sugar, salt and fat taxes. 
1
£
%
There is significant potential 
income that can be generated 
through fiscal measures on 
sugar, salt and fat taxes.
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  Introduce mandatory controls on  
 supermarket price promotions  
 for unhealthy food and drink
40% of food purchased to eat at home is on 
promotion, and disproportionately includes food 
and drink high in sugar content – on average, a 
household would have to spend £630 extra each year 
to buy their annual selection of promoted items at 
full price.100 Moreover, the health burden particularly 
impacts groups with lower incomes as their dietary 
patterns are heavily influenced by cost.101 
Analysis has found that promotions lead to 
consumers swapping one brand for another, but 
also lead to a 20% expansion of the category over 
time; thus, consumers are buying more food and 
spending more money despite the promotion.102 
Public Health England estimated that if future 
promotions were banned, 6.1% would be cut in 
overall sugar volume.103 It is therefore crucial  
that supermarkets play their role in promoting 
healthier eating.
3
  Offer weight loss surgery  
  to obese people with diabetes
There is a significant benefit to offering more obese 
people weight loss surgery. Despite the growing 
levels of obesity in the UK, in contrast to many 
other countries, the number of surgical weight loss 
procedures in the NHS is falling.104 
Weight loss surgery costs £6,000 in the short-term, 
but is far outweighed by the costs that would be 
averted by avoiding obesity-related complications 
of liver disease, long-term diabetes or many other 
health conditions. Weight loss surgery is highly 
effective and pays for itself within less than two to 
three years.105 
Patients experience significant health improvement 
following weight loss surgery as they are:106 
• Nine times more likely to see major diabetes  
 improvement
• 70% less likely to have a heart attack
• Likely to see beneficial impact in  
 hypertension, angina and sleep apnoea
4
MYTHBUSTER
MYTH: There is little evidence that the levy will work.
EVIDENCE: Levies have worked in other countries:95
• In Mexico, a $1 peso excise tax, on average,  
 led to a 12% fall in consumption in 12 months
• In Hungary, 40% of manufacturers reduced  
 or eliminated sugar following a tax on sugary  
 products
Weight loss surgery is highly 
effective and pays for itself within  
less than two to three years. 
!
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The burden of viral hepatitis has grown considerably in recent decades to become one of the main causes of liver 
disease in the UK. Unlike the other chief causes, data has been more challenging to collect in order to understand the 
complete picture of the burden and associated costs of viral hepatitis.
The number of individuals chronically infected with hepatitis C in the UK has been estimated to be 216,000,107 although 
other studies have suggested the true figure could be as high as 466,000 with 86% unaware they are infected.108  
The prevalence of hepatitis B has also become a major challenge for the UK, with a similarly large pool of people 
affected by the disease.109  
Marginalised populations, such as people who inject drugs, prisoners and immigrant populations,110 are at an elevated 
risk.111,112,113,114 In the UK, 95% of new chronic hepatitis B infections can be found in migrant populations, and 90% of 
chronic hepatitis C infections occur in people who inject drugs or have done previously.115 
Disease detection and treatment of patients affected by viral hepatitis in the UK is often sub-optimal in comparison 
to other European countries.116 No testing for hepatitis B or C at the time of immigration visa applications is in place 
unlike in many countries around the world.117 
Health and care system costs
The consequences of viral hepatitis take time to be 
felt, but if left untreated, it can lead to severe liver 
disease, including cirrhosis, hepatocellular carcinoma 
and end-stage liver failure. The management of these 
complications can put a significant financial strain on 
the health system. Between 2010 and 2015, preliminary 
estimates of cases of hepatitis C-related cirrhosis or 
hepatocellular carcinoma increased from 1,336 to 1,692 
in England,119 indicating that the burden of hepatitis 
C-related complications on the health system is rising. 
In view of the high health and financial burden 
associated with the management of complications of 
advanced liver disease, prevention of viral hepatitis 
must be prioritised. For those living with the disease 
– many of whom are unaware – access to testing, 
early diagnosis and appropriate treatment is crucial. 
Research has shown low levels of hepatitis B testing 
amongst migrants in the UK, and highlights the 
importance of primary care in this area.120 
Work previously undertaken by West Midlands Public 
Health England with a prison in the region identified a 
number of findings and recommendations on how to 
improve detection and treatment of hepatitis B and C 
amongst prisoners.121 
The recent introduction of novel oral antiviral treatments 
for hepatitis C into the NHS offers new opportunities. 
With significantly higher cure rates and more tolerable 
side-effect profiles than historical treatments, the health 
system needs to maximise their potential in averting 
hepatitis C-related complications. Through establishing 
a system of operational delivery networks, the NHS 
targeted to treat 10,000 patients for hepatitis C in 2016122 
and increase this to 15,000 per year by 2021.123  
This is up from an average of  
5,100 in previous years. 
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Viral hepatitis
Productivity
The impact of viral hepatitis is felt by businesses 
as well. Hepatitis C alone was estimated to be 
responsible for productivity losses of as high as 
£367m due to absenteeism and presenteeism.128 
An international study assessing five European 
countries found that hepatitis C treatment for 
patients resulted in improvements in work 
productivity. Absenteeism and presenteeism  
saw a 16.28% and 19.53% improvement 
respectively in the study, leading to savings  
of £435 million annually.129 
The new treatments come at a cost, with the NHS 
making a £190m ring-fenced investment into the new 
antiviral medicines in 2015,124 but their use is deemed 
cost-effective by NICE, helping to avert an even higher 
cost of complications of advanced liver disease. 
A 2014 study found that complete treatment coverage 
for individuals needing it would cost £1.5bn over 
the next 30 years; however, under current levels of 
treatment, the total healthcare cost of the hepatitis 
C-infected population would be £4.7bn due to the 
complications arising from failing to treat all those 
affected by the disease.125 
Furthermore, after many years of rising deaths due to 
hepatitis C, 2015 saw an 11% fall in the number. This 
coincided with a 40% increase the number of people 
who received treatment.126 
Research has concluded that hepatitis C treatment 
should be provided to people who inject drugs 
regardless of the severity of their condition. This has 
the potential to be more cost-effective than treating 
patients in a similar condition but who pose less 
disease transmission risk.127 
MYTHBUSTER
MYTH: People who inject drugs are only  
able to start treatment once they stop injecting
EVIDENCE: National and European treatment 
guidelines make it clear that treatment must be 
considered for people who inject drugs, provided 
they wish to receive treatment and are able and 
willing to maintain regular appointments.118
Hepatitis C treatment for 
patients resulted in improvements 
in work productivity.
!
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 Some important action is already underway, notably 
the planned implementation of a universal hepatitis 
B vaccination for babies taking effect from October 
2017. A previous study of a vaccination programme 
estimated the cost to be £229,000, outweighed 
by net savings of approximately £288,000 or 
potentially as high as £489,000.130 However, it will 
take a significant length time for the impact to be 
felt. Additional measures are required to achieve 
progress and avert the high costs of complications 
of viral hepatitis-related liver disease.
What can be done?
Both the costs of new treatments and managing the complications caused by viral 
hepatitis could be reduced through effective prevention measures and early diagnosis. 
  Improve access to testing  
 and diagnosis of hepatitis
Further initiatives that help to raise awareness 
amongst the public about the disease are required, 
but crucially, healthcare professionals in primary 
care and drug services must also be further 
educated. Diagnosing hepatitis at an earlier 
stage will avoid the health and cost burden of 
complications of advanced liver disease.
Public health budgets must be protected and 
increased to enable effective testing and diagnosis 
in the community. Targeted efforts should be made 
to improve local provision to offer testing to groups 
who are at greatest risk and/or not in regular 
contact with health services. Drug users, the 
homeless population and prison population should 
be a key focus.
We welcome steps that have been taken to improve 
diagnosis rates within this cohort. The Hepatitis C 
Trust’s mobile testing unit for the homeless found 
8% of the 1,731 tested to be positive for hepatitis 
C between 2011 and 2014131 – this initiative should 
be expanded. In addition, bloodborne virus opt-
out testing for new receptions to prisons has been 
important, and we would also welcome opt-out 
testing in drug services.
Investing in more of these innovative approaches  
to accessing testing and diagnosis will help to  
drive change.
2
 Immunise all individuals  
 with risk factors for hepatitis B
Universal immunisation for babies is an important 
step, but will only cover those born after 2018. 
Immunisation should be extended to individuals  
with risk factors who will not be captured by the  
new programme. This would help to achieve 
progress at a much quicker pace, reducing the 
current population with hepatitis B.
1
£
 Protect harm  
 reduction services
Improving testing and diagnosis is crucial, but 
harm reduction services must also play a major 
role in reducing the burden of hepatitis. These 
services must remain funded and simple to access 
for individuals in need. Schemes including needle 
exchange and opioid substitution are instrumental 
in rehabilitating injecting drug users.
3
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